Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

E. Dewey, Frederick; Gusarova, Viktoria; L. Dunbar, Richard; O’Dushlaine, Colm; Schurmann, Claudia; Gottesman, Omri; McCarthy, Shane; V. Van Hout, Cristopher; Bruse, Shannon; M. Dansky, Hayes; B. Leader, Joseph; F. Murray, Michael; D. Ritchie, Marylyn; Lester Kirchner, H.; Habegger, Lukas; Lopez, Alex; S. Penn, John; Sha Zhao, An; Shao, Weiping; Stahl, Neil; Murphy, Andrew; Hamon, Sara; Bouzelmat, Aurelie; Zhang, Rick; Shumel, Brad; Pordy, Robert; A. Gipe, Daniel; Herman, Gary; Huey‐Herng Sheu, Wayne; Lee, I‐Te; Liang, Kae‐Woei; Guo, Xiuqing; I. Rotter, Jerome; I. Chen, Yii‐Der; E. Kraus, William; H. Shah, Svati; M. Damrauer, Scott; Small, Aeron; J. Rader, Daniel; Berg Wulff, Anders; G. Nordestgaard, Børge; Tybjærg‐Hansen, Anne; M. van den Hoek, Anita; M.G. Princen, Hans; H. Ledbetter, David; J. Carey, David; D. Overton, John; G. Reid, Jeffrey; J. Sasiela, William; Banerjee, Poulabi; R. Shuldiner, Alan; B. Borecki, Ingrid; M. Teslovich, Tanya; D. Yancopoulos, George; Mellis, Scott; Gromada, Jesper; Baras, Aris

doi:10.1056/nejmoa1612790

Public

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Published in New England Journal of Medicine • May 24, 2017

Authors:

Frederick E. Dewey

Viktoria Gusarova

Richard L. Dunbar

Abstract

BACKGROUND: Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagoni...

Subject

Disease

Medicine

Genetics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!